trending Market Intelligence /marketintelligence/en/news-insights/trending/5xxhk8gxphsexijjhhxlyq2 content esgSubNav
In This List

Madrigal Pharmaceuticals prices, upsizes stock offering to $300M

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Madrigal Pharmaceuticals prices, upsizes stock offering to $300M

Madrigal Pharmaceuticals Inc. priced an offering of 983,607 shares at $305 apiece to raise $300 million, $100 million more than what it previously expected to raise.

The West Conshohocken, Pa.-based biotechnology company's executives and existing shareholders are looking to sell a separate 363,625 shares, also at the same price. The company will not receive any proceeds from the secondary offering.

Goldman Sachs & Co. LLC is the sole book-running manager of the offering, which is expected to close by June 11. Cowen is a lead manager, while JMP Securities, Roth Capital Partners and H.C. Wainwright & Co. are co-managers.

The underwriters can buy up to an additional 202,084 shares from the company.